Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Arthritis Rheum. 2002;46(8):2121–31.
Cyclophosphamide (with AZA) produces good long-term results in LN.
Differences in outcomes such as End Stage Renal Disease in LN are often only significant after five years. Despite this, many therapeutic trials in lupus are short- or medium-term.
In this 10-year follow-up study, Houssiau et al compare low- and high-dose cyclophosphamide, and confirm that a low-dose cyclophosphamide and AZA regimen produces good long-term clinical results.
